The Role of Inflammatory Markers in Predicting Autoimmune Comorbidities Among Patients with Type 1 Diabetes Mellitus

Year 2025, Volume: 7 Issue: 4, 135 - 140, 29.10.2025

Nazif Yalçın , Nizameddin Koca

https://doi.org/10.46310/tjim.1797119

Abstract

Background: Type 1 diabetes mellitus (T1DM) frequently coexists with other autoimmune diseases, which may enhance systemic inflammation and affect clinical outcomes. Novel inflammatory indices, including the pan-immune-inflammation value (PIV) and systemic immune-inflammation index (SII), have emerged as potential markers of immune activation. This study aimed to evaluate whether these markers could distinguish T1DM patients with comorbid autoimmune diseases from those without.
Methods: In this retrospective analysis, patients with T1DM were stratified according to the presence or absence of comorbid autoimmune diseases. Demographic, metabolic, laboratory, and inflammatory parameters, including PIV, SII, and leukocyte subsets, were compared between groups using appropriate non-parametric tests.
Results: Patients with autoimmune comorbidities exhibited significantly higher PIV (559.5 ± 390.5 vs. 225.5 ± 187.5, p<0.001) and SII (810.6 ± 407.7 vs. 503.1 ± 257.9, p<0.001) values compared with those without autoimmune conditions. Neutrophil and monocyte counts were also elevated (neutrophils: 5.7 ± 1.9 vs. 4.0 ± 1.3, p<0.001; monocytes: 0.68 ± 0.25 vs. 0.50 ± 0.14, p<0.001), whereas lymphocyte counts did not differ significantly (p=0.127). No statistically significant differences were observed in age, BMI, glycemic control (HbA1c: 8.7 ± 1.7% vs. 8.6 ± 1.6%, p=0.494), lipid profiles, or other standard laboratory parameters.
Conclusion: Patients with T1DM and comorbid autoimmune diseases exhibit a markedly elevated inflammatory profile, as indicated by PIV and SII, despite having similar metabolic and demographic characteristics. These findings suggest that inflammatory indices may serve as adjunctive biomarkers for the detection or monitoring of autoimmune comorbidities in T1DM, warranting further prospective studies to evaluate their diagnostic and prognostic utility.

Keywords

Type 1 DM , PIV , SII , autoimmune disease , inflammatory markers

Ethical Statement

The study was approved by the Institutional Review Board of the participating center (Approval Date: March 19, 2025; Decision No: 2025-6/1) and conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.

References

• Lucier J, Mathias PM. Type 1 Diabetes. In: StatPearls. Treasure Island (FL): StatPearls Publishing; October 5, 2024
• Yalçın N, Paşalı Kilit T, Onbaşı K, Koca N. Evaluation of osteoporosis and associated factors in patients with type 1 diabetes mellitus. Sakarya Med J. 2025;15(1):47-58. doi:10.31832/smj.1598017
• Popoviciu MS, Kaka N, Sethi Y, Patel N, Chopra H, Cavalu S. Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine. Journal of Personalized Medicine. 2023; 13(3):422. https://doi.org/10.3390/jpm13030422
• Dong Y, Tang M.et all. Predictive value of systemic immune-inflammation index in patients with diabetes mellitus: a systematic review and meta-analysis. Front. Endocrinol., 23 September 2025 Sec. Clinical Diabetes Volume 16 - 2025 | https://doi.org/10.3389/fendo.2025.1617814
• Wang H, Huang Z, Wang J, et al. Predictive value of system immune-inflammation index for the severity of coronary stenosis in patients with coronary heart disease and diabetes mellitus. Sci Rep. 2024;14(1):31370. Published 2024 Dec 28. doi:10.1038/s41598-024-82826-5
• Karaaslan T, Karaaslan E. Predictive Value of Systemic Immune-inflammation Index in Determining Mortality in COVID-19 Patients. J Crit Care Med (Targu Mures). 2022;8(3):156-164. Published 2022 Aug 12. doi:10.2478/jccm-2022-0013
• Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev. 2016;15(7):644-648. doi:10.1016/j.autrev.2016.02.017
• Zhang Y, Yue Y, Sun Z, et al. Pan-immune-inflammation value and its association with all-cause and cause-specific mortality in the general population: a nationwide cohort study. Front Endocrinol (Lausanne). 2025;16:1534018. Published 2025 Apr 30. doi:10.3389/fendo.2025.1534018
• Wu Y, Huang Y. Et all. Systemic immune-inflammation index as a versatile marker in autoimmune diseases. Front. Immunol., 07 August 2025 Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders Volume 16 – 2025 https://doi.org/10.3389/fimmu.2025.1621209
• Samuelsson J, Bertilsson R, Bülow E, et al. Autoimmune comorbidity in type 1 diabetes and its association with metabolic control and mortality risk in young people: a population-based study. Diabetologia. 2024;67(4):679-689. doi:10.1007/s00125-024-06086-8
• Yang CH, Wang XY, Zhang YH, Ding N. SIRI and SII as potential biomarkers of disease activity and lupus nephritis in systemic lupus erythematosus. Front Immunol. 2025;16:1530534. Published 2025 Jan 31. doi:10.3389/fimmu.2025.1530534
• Liu B, Wang J, Li YY, Li KP, Zhang Q. The association between systemic immune-inflammation index and rheumatoid arthritis: evidence from NHANES 1999-2018. Arthritis Res Ther. 2023;25(1):34. Published 2023 Mar 4. doi:10.1186/s13075-023-03018-6
• Mao C, Cui X, Zhang S. The value of the systemic immune-inflammation index in assessing disease severity in autoimmune encephalitis. Int J Neurosci. Published online October 1, 2024. doi:10.1080/00207454.2024.2410033
• Ozdemir A, Baran E, Kutu M, Celik S, Yılmaz M. Could systemic immune inflammation index be a new parameter for diagnosis and disease activity assessment in systemic lupus erythematosus?. Int Urol Nephrol. 2023;55(1):211-216. doi:10.1007/s11255-022-03320-3
• Eyiol H, Eyiol A, Sahin AT. Association of the Pan-Immune-Inflammatory Value (PIV) and HALP score with disease prognosis and recovery in patients with acute pericarditis: An observational cohort study. Medicine (Baltimore). 2025;104(37):e44460. doi:10.1097/MD.0000000000044460
• Tutan D, Doğan AG. Pan-Immune-Inflammation Index as a Biomarker for Rheumatoid Arthritis Progression and Diagnosis. Cureus. 2023;15(10):e46609. Published 2023 Oct 6. doi:10.7759/cureus.46609
• Nederstigt, C.; Uitbeijerse, B.S.; Janssen, L.G.M.; Corssmit, E.P.M.; de Koning, E.J.P.; Dekkers, O.M. Associated Auto-Immune Disease in Type 1 Diabetes Patients: A Systematic Review and Meta-Analysis. Eur. J. Endocrinol. 2019, 180, 135–144.
• Volta, U.; Tovoli, F.; Caio, G. Clinical and Immunological Features of Celiac Disease in Patients with Type 1 Diabetes Mellitus. Expert Rev. Gastroenterol. Hepatol. 2011, 5, 479–487
• Krzewska, A.; Ben-Skowronek, I. Effect of Associated Autoimmune Diseases on Type 1 Diabetes Mellitus Incidence and Metabolic Control in Children and Adolescents. BioMed Res. Int. 2016, 2016, 6219730